Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Lucas BaslerHubert Szymon GabryśSabrina A HoganMatea PavicMarta BogowiczDiem VuongStephanie Tanadini-LangRobert FoersterKen KuduraMartin W HuellnerReinhard DummerMatthias GuckenbergerMitchell P LevesquePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Noninvasive PET/CT-based radiomics, especially in combination with blood parameters, are promising biomarkers for early differentiation of pseudoprogression, potentially avoiding added toxicity or delayed treatment switch.